DAVID TIN CHU M.D. NPI 1750585287

NPI Details

David Tin Chu, M.D. is a hematology and oncology internal medicine in Port Jefferson Station, NY with 22 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. David Tin Chu, M.D. NPI is 1750585287. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

49 NESCONSET HWY
PORT JEFFERSON STATION, NY
ZIP 11776-628
Phone: (631) 751-3000
Fax: (631) 675-2001

The NPI 1750585287 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram (HCPCS:J1442)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Magnesium level (HCPCS:83735)
• Uric acid level, blood (HCPCS:84550)
• Phosphate level (HCPCS:84100)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99490)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Vitamin d-3 level (HCPCS:82306)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Protein measurement, serum (HCPCS:84165)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Red blood count, manual test (HCPCS:85044)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Blood test, clotting time (HCPCS:85610)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Folic acid level, serum (HCPCS:82746)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion, normal saline solution, 250 cc (HCPCS:J7050)
• Ige (immune system protein) level (HCPCS:82785)
• Measurement c-reactive protein for detection of infection or inflammation, high sensitivity (HCPCS:86141)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Urinalysis, manual test (HCPCS:81002)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen (HCPCS:87635)
• Hemoglobin a1c level (HCPCS:83036)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Drawing of blood for a medical problem (HCPCS:99195)
• Acute hepatitis panel (HCPCS:80074)
• Transitional care management services for problem of high complexity (HCPCS:99496)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Testosterone (hormone) level, total (HCPCS:84403)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Bilirubin level, total (HCPCS:82247)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Detection test by nucleic acid for multiple organisms, amplified probe(s) technique (HCPCS:87801)
• Albumin (protein) level (HCPCS:82040)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Liver function blood test panel (HCPCS:80076)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Blood creatinine level (HCPCS:82565)
• Parathormone (parathyroid hormone) level (HCPCS:83970)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Rheumatoid factor level (HCPCS:86431)
• Injection, lorazepam, 2 mg (HCPCS:J2060)
• Lactic acid level (HCPCS:83605)
• Detection test by nucleic acid for multiple types influenza virus (HCPCS:87502)
• Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99439)
• Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month (HCPCS:99426)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) (HCPCS:G0506)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Bilirubin level, direct (HCPCS:82248)
• Coagulation assessment blood test, plasma or whole blood (HCPCS:85730)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Transitional care management services for problem of moderate complexity (HCPCS:99495)
• Coagulation function measurement, d-dimer; quantitative (HCPCS:85379)
• Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody (HCPCS:86769)
• Gene analysis (calreticulin), common variants (HCPCS:81219)
• Gene analysis (janus kinase 2) variant (HCPCS:81270)
• Gene analysis (janus kinase 2) targeted sequence analysis (HCPCS:81279)
• Gene analysis (mpl proto-oncogene, thrombopoietin receptor) for detection of common variants (HCPCS:81338)
• Molecular pathology procedure; physician interpretation and report (HCPCS:G0452)

The enumeration date for this NPI number is 6/11/2007 and was last updated on 1/31/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.